Nuveen
MAZE

Nuveen’s Maze Therapeutics MAZE Stock Holding History

Nuveen’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.34M Buy
78,468
+15,108
+24% +$396K ﹤0.01% 2499
2026
Q1 		$1.89M Buy
63,360
+6,102
+11% +$269K ﹤0.01% 2301
2025
Q4 		$2.37M Buy
57,258
+26,954
+89% +$926K ﹤0.01% 2213
2025
Q3 		$786K Buy
30,304
+18,929
+166% +$320K ﹤0.01% 2729
2025
Q2 		$140K Hold
11,375
– – ﹤0.01% 3221
2025
Q1 		$125K Buy
+11,375
New +$137K ﹤0.01% 3194

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Nuveen's MAZE Position: Q2 2026 in Review

Nuveen increased its Maze Therapeutics (MAZE) stake by 24% in Q2 2026, buying an estimated $396K and bringing the position to 78,468 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2499.

Nuveen first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.37M in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Nuveen held 78,468 shares of Maze Therapeutics worth $2.34M as of Q2 2026.
  • Nuveen bought 15,108 Maze Therapeutics shares in Q2 2026, an estimated $396K.
  • Maze Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2499 holding.
  • Nuveen first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Nuveen's Maze Therapeutics position peaked at $2.37M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.